Adagene (ADAG) Stock Forecast & Price Target

Adagene is compelling because its masked SAFEbody platform appears to convert a difficult CTLA-4 mechanism into a potentially differentiated efficacy-safety profile, with muzastotug showing dose-driven responses in Phase 1b and a randomized Phase 2 readout expected in 1H27. The company also has multiple shots on goal beyond MSS CRC, including a Roche-sponsored HCC triplet that delivered a 66.7% ORR in six patients and a first-in-human T-cell engager program expected to dose this quarter, which broadens platform validation. Financially, it reported $1.6M in licensing revenue in 1H26, ended 1H26 with about $128M in cash and equivalents, and its runway is expected to last into late 2028, reducing near-term financing pressure.

Adagene is fundamentally challenged by weak evidence quality and uncertain durability of its clinical signal: ADG126’s 36% ORR came from a tiny n=14, non-randomized cohort, with no monotherapy or pembrolizumab-only control to isolate contribution, so the apparent benefit could regress materially in Phase 2. Toxicity remains material despite the masking strategy, with 50% grade 3 TRAEs and 29% grade 3 diarrhea/colitis at the 20 mg/kg loading cohort, while class precedent in masked CTLA-4 has been mixed to poor and the difficult MSS CRC setting has repeatedly punished single-arm enthusiasm. Financially, the company has only about $122M in net cash versus registrational-scale spending needs, implying likely dilution or reliance on partnering, while regulatory and China-related cross-border risks add further uncertainty to execution.